» Articles » PMID: 16445274

Hyperkalemia

Overview
Specialty Public Health
Date 2006 Feb 1
PMID 16445274
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperkalemia is a potentially life-threatening metabolic problem caused by inability of the kidneys to excrete potassium, impairment of the mechanisms that move potassium from the circulation into the cells, or a combination of these factors. Acute episodes of hyperkalemia commonly are triggered by the introduction of a medication affecting potassium homeostasis; illness or dehydration also can be triggers. In patients with diabetic nephropathy, hyperkalemia may be caused by the syndrome of hyporeninemic hypoaldosteronism. The presence of typical electrocardiographic changes or a rapid rise in serum potassium indicates that hyperkalemia is potentially life threatening. Urine potassium, creatinine, and osmolarity should be obtained as a first step in determining the cause of hyperkalemia, which directs long-term treatment. Intravenous calcium is effective in reversing electrocardiographic changes and reducing the risk of arrhythmias but does not lower serum potassium. Serum potassium levels can be lowered acutely by using intravenous insulin and glucose, nebulized beta2 agonists, or both. Sodium polystyrene therapy, sometimes with intravenous furosemide and saline, is then initiated to lower total body potassium levels.

Citing Articles

Bradycardia, Renal Failure, Atrioventricular (AV) Nodal Blockers, Shock, and Hyperkalemia (BRASH) Syndrome: A Confounder in the Clinical Practice.

Certal M, Mimoso D, Marques B, Cerqueira E, Exposito B Cureus. 2024; 16(10):e72793.

PMID: 39618623 PMC: 11608123. DOI: 10.7759/cureus.72793.


Are Newer Potassium Binding Agents Truly Better? Rethinking Sodium Polystyrene Sulfate and Emerging Therapies for Hyperkalemia.

Mehta M, Auguste B J Gen Intern Med. 2024; 40(3):516-517.

PMID: 39375313 PMC: 11861442. DOI: 10.1007/s11606-024-09107-9.


Efficacy of anti-hyperkalemic agents during cardiopulmonary resuscitation in out-of-hospital cardiac arrest.

Tak Lee G, Jeong D, Park J, Lee S, Kim T, Yoon H Heliyon. 2024; 10(16):e36345.

PMID: 39253152 PMC: 11381597. DOI: 10.1016/j.heliyon.2024.e36345.


The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.

Arici M, Altun B, Araz M, Atmaca A, Demir T, Ecder T Front Med (Lausanne). 2024; 11:1384454.

PMID: 38947237 PMC: 11214281. DOI: 10.3389/fmed.2024.1384454.


Hyperkalemia: Pharmacotherapies and Clinical Considerations.

Sinnathamby E, Banh K, Barham W, Hernandez T, De Witt A, Wenger D Cureus. 2024; 16(1):e52994.

PMID: 38406030 PMC: 10894645. DOI: 10.7759/cureus.52994.